ReviewGels (Basel, Switzerland)2026
Hydrogel-Based Delivery of Ion Channel Modulators for Cancer Therapy: Current Advances and Future Perspectives.
Review in Gels (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains one of the deadliest health problems worldwide. Traditional and multifaceted treatment approaches often fail to achieve expected outcomes. Consequently, it is essential to develop innovative and effective treatment strategies. Ion channels play a critical role in regulating fundamental cellular events, such as cell proliferation, differentiation, and programmed cell death. In this context, the current literature increasingly demonstrates the potential of ion channel modulators to suppress tumor growth. Approaches targeting ion channels have gained increasing importance in cancer research in recent years. Drug delivery systems, particularly hydrogels, play crucial roles in enhancing the therapeutic efficacy of these agents. This review addresses the current developments in the antitumor effects of ion channel modulators within the context of hydrogel-based delivery strategies. Considering the pharmacokinetic advantages, controlled release properties, and targeted delivery capacity of these systems, their biocompatibility, stability, and limitations in clinical applications are also evaluated. Thus, innovative perspectives are presented to address the shortcomings in current cancer treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.